UPDATE: Citigroup Upgrades Edwards Lifesciences Corp. to Buy, Raises PT on Upcoming Catalysts, Attractive Risk/Reward

In a report published Wednesday, Citigroup analyst Amit Bhalla upgraded the rating on Edwards Lifesciences Corp. EW from Neutral to Buy, and raised the price target from $75.00 to $86.00. In the report, Citigroup noted, “We are upgrading EW to Buy (from a Neutral) and are increasing our target price to $86 (from $75) based on an increased P/E multiple of 23x (from 20x) on our unchanged 2014 EPS of $3.75. While the economics of TAVI procedures continues to be a concern, we believe the stock adequately reflects a slower US adoption curve and competitive entrants in Europe. With the stock down 17% YTD (vs. S&P +19%) and trading at a 4-year low relative to medtech peers, we believe several upcoming catalysts support an attractive entry point and favorable risk/reward trade off.” Edwards Lifesciences Corp. closed on Tuesday at $74.73.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsAmit BhallaCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!